NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
Employees - 6,
CEO - Mr. Alexander Zwyer M.B.A.,
Sector - Healthcare,
Country - CH,
Market Cap - 3.95M
Altman ZScore(max is 10): -148.47, Piotroski Score(max is 10): 1, Working Capital: $-6525649, Total Assets: $1193458, Retained Earnings: $-72409318, EBIT: -20701250, Total Liabilities: $10461716, Revenue: $0
AryaFin Target Price - $-0.02 - Current Price $1.95 - Analyst Target Price $160.00
| Ticker | NLSP |
| Index | - |
| Curent Price | 1.95 |
| Change | -18.07% |
| Market Cap | 3.95M |
| Average Volume | 375.16K |
| Income | -6.60M |
| Sales | 0.00M |
| Book Value/Share | -0.24 |
| Cash/Share | 0.27 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 4 |
| Moving Avg 20days | -22.09% |
| Moving Avg 50days | -43.61% |
| Moving Avg 200days | -67.25% |
| Shares Outstanding | 39.43M |
| Earnings Date | - |
| Inst. Ownership | 6.10% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | - |
| Price/Cash | 7.18 |
| Price/FCF | - |
| Quick Ratio | 0.15 |
| Current Ratio | 0.15 |
| Debt/Equity | - |
| Return on Assets | -380.82% |
| Return on Equity | - |
| Return on Investment | - |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 34.16 |
| BETA(β) | -0.41 |
| From 52week Low | 12.72% |
| From 52week High | -91.99% |
| EPS | -0.19 |
| EPS next Year | - |
| EPS next Qtr | - |
| EPS this Year | - |
| EPS next 5 Year | - |
| EPS past 5 Year | 7.15% |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | 61.71% |
| Sales Y/Y | - |
| EPS Q/Q | 75.68% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | 0.00% |
| ATR(14) | 0.40 |
| Perf Week | 2.09% |
| Perf Month | -40.73% |
| Perf Quarter | -64.05% |
| Perf Year | -89.28% |
| Perf YTD | -91.74% |
| Target Price | 160.00 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer